<table>
<thead>
<tr>
<th><strong>Core Safety Profile</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active substance:</strong></td>
</tr>
<tr>
<td><strong>Pharmaceutical form(s)/strength:</strong></td>
</tr>
<tr>
<td><strong>P-RMS:</strong></td>
</tr>
<tr>
<td><strong>Date of FAR:</strong></td>
</tr>
</tbody>
</table>
4.3. Contraindications

- Hypersensitivity to the active substance or to any of the excipients.
- Liver insufficiency or liver function impairment.
- Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy.

In addition, as with other beta-blocking agents, is contra-indicated in:

- sick sinus syndrome, including sino-atrial block.
- second and third degree heart block (without a pacemaker).
- history of bronchospasm and bronchial asthma.
- untreated phaeochromocytoma.
- metabolic acidosis.
- bradycardia (heart rate < 60 bpm prior to start therapy).
- hypotension (systolic blood pressure < 90 mmHg).
- severe peripheral circulatory disturbances.

4.4. Special warnings and precautions for use

See also 4.8 Undesirable effects.

The following warnings and precautions apply to beta-adrenergic antagonists in general.

Anaesthesia
Continuation of beta-blockade reduces the risk of arrhythmias during induction and intubation. If beta-blockade is interrupted in preparation for surgery, the beta-adrenergic antagonist should be discontinued at least 24 hours beforehand. Caution should be observed with certain anaesthetics that cause myocardial depression. The patient can be protected against vagal reactions by intravenous administration of atropine.

Cardiovascular
In general, beta-adrenergic antagonists should not be used in patients with untreated congestive heart failure (CHF), unless their condition has been stabilised.

In patients with ischaemic heart disease, treatment with a beta-adrenergic antagonist should be discontinued gradually, i.e. over 1-2 weeks. If necessary replacement therapy should be initiated at the same time, to prevent exacerbation of angina pectoris.

Beta-adrenergic antagonists may induce bradycardia: if the pulse rate drops below 50-55 bpm at rest and/or the patient experiences symptoms that are suggestive of bradycardia, the dosage should be reduced.

Beta-adrenergic antagonists should be used with caution:
- in patients with peripheral circulatory disorders (Raynaud's disease or syndrome, intermittent claudication), as aggravation of these disorders may occur;
- in patients with first degree heart block, because of the negative effect of beta-blockers on conduction time;
- in patients with Prinzmetal's angina due to unopposed alphareceptor mediated coronary artery vasoconstriction: beta-adrenergic antagonists may increase the number and duration of anginal attacks.

Combination of nebivolol with calcium channel antagonists of the verapamil and diltiazem type, with Class I antiarrhythmic drugs, and with centrally acting...
antihypertensive drugs is generally not recommended, for details please refer to section 4.5.

Metabolic/Endocrinological

...does not affect glucose levels in diabetic patients. Care should be taken in diabetic patients however, as nebivolol may mask certain symptoms of hypoglycaemia (tachycardia, palpitations). Beta-adrenergic blocking agents may mask tachycardic symptoms in hyperthyroidism. Abrupt withdrawal may intensify symptoms.

Respiratory

In patients with chronic obstructive pulmonary disorders, beta-adrenergic antagonists should be used with caution as airway constriction may be aggravated.

Other

Patients with a history of psoriasis should take beta-adrenergic antagonists only after careful consideration. Beta-adrenergic antagonists may increase the sensitivity to allergens and the severity of anaphylactic reactions.

The initiation of Chronic Heart Failure treatment with nebivolol necessitates regular monitoring. For the posology and method of administration please refer to section 4.2. Treatment discontinuation should not be done abruptly unless clearly indicated. For further information please refer to section 4.2.

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

Pharmacodynamic interactions:

The following interactions apply to beta-adrenergic antagonists in general.

Combinations not recommended:

Class I antiarrhythmics (quinidine, hydroquinidine, cibenzoline, flecainide, disopyramide, lidocaine, mexiletine, propafenone): effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect increased (see section 4.4).

Calcium channel antagonists of verapamil/diltiazem type: negative influence on contractility and atrio-ventricular conduction. Intravenous administration of verapamil in patients with ß-blocker treatment may lead to profound hypotension and atrio-ventricular block (see section 4.4).

Centrally-acting antihypertensives (clonidine, guanfacin, moxonidine, methyldopa, rilmenidine): concomitant use of centrally acting antihypertensive drugs may worsen heart failure by a decrease in the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation) (see section 4.4). Abrupt withdrawal, particularly if prior to beta-blocker discontinuation, may increase risk of “rebound hypertension”.
**Combinations to be used with caution**

Class III antiarrhythmic drugs (Amiodarone): effect on atrio-ventricular conduction time may be potentiated.

Anaesthetics - volatile halogenated: concomitant use of beta-adrenergic antagonists and anaesthetics may attenuate reflex tachycardia and increase the risk of hypotension (see section 4.4). As a general rule, avoid sudden withdrawal of beta-blocker treatment. The anaesthesiologist should be informed when the patient is receiving /.../.

Insulin and oral antidiabetic drugs: although nebivolol does not affect glucose level, concomitant use may mask certain symptoms of hypoglycaemia (palpitations, tachycardia).

Baclofen (antispastic agent), amifostine (antineoplastic adjunct): concomitant use with antihypertensives is likely to increase the fall in blood pressure, therefore the dosage of the antihypertensive medication should be adjusted accordingly.

**Combinations to be considered**

Digitalis glycosides: concomitant use may increase atrio-ventricular conduction time. Clinical trials with nebivolol have not shown any clinical evidence of an interaction. Nebivolol does not influence the kinetics of digoxin.

Calcium antagonists of the dihydropyridine type (amlodipine, felodipine, lacidipine, nifedipine, nicardipine, nimodipine, nitrendipine): concomitant use may increase the risk of hypotension, and an increase in the risk of a further deterioration of the ventricular pump function in patients with heart failure cannot be excluded.

Antipsychotics, antidepressants (tricyclics, barbiturates and phenothiazines): concomitant use may enhance the hypothesensive effect of the beta-blockers (additive effect).

Non steroidal anti-inflammatory drugs (NSAID): no effect on the blood pressure lowering effect of nebivolol.

Sympathicomimetic agents: concomitant use may counteract the effect of beta-adrenergic antagonists. Beta-adrenergic agents may lead to unopposed alpha-adrenergic activity of sympathicomimetic agents with both alpha- and beta-adrenergic effects (risk of hypertension, severe bradycardia and heart block).

**Pharmacokinetic interactions:**

As nebivolol metabolism involves the CYP2D6 isoenzyme, co-administration with substances inhibiting this enzyme, especially paroxetine, fluoxetine, thioridazine and quinidine may lead to increased plasma levels of nebivolol associated with an increased risk of excessive bradycardia and adverse events.

Co-administration of cimetidine increased the plasma levels of nebivolol, without changing the clinical effect. Co-administration of ranitidine did not affect the pharmacokinetics of nebivolol. Provided /.../is taken with the meal, and an antacid between meals, the two treatments can be co-prescribed.

Combining nebivolol with nicardipine slightly increased the plasma levels of both drugs, without changing the clinical effect. Co-administration of alcohol, furosemide or hydrochlorothiazide did not affect the pharmacokinetics of nebivolol. Nebivolol does not affect the pharmacokinetics and pharmacodynamics of warfarin.
4.6 Pregnancy and lactation

Use in pregnancy
Nebivolol has pharmacological effects that may cause harmful effects on pregnancy and/or the foetus/newborn. In general, beta-adrenoceptor blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour. Adverse effects (e.g. hypoglycaemia and bradycardia) may occur in the foetus and newborn infant. If treatment with beta-adrenoceptor blockers is necessary, beta1-selective adrenoceptor blockers are preferable. Nebivolol should not be used during pregnancy unless clearly necessary. If treatment with nebivolol is considered necessary, the uteroplacental blood flow and the foetal growth should be monitored. In case of harmful effects on pregnancy or the foetus alternative treatment should be considered. The newborn infant must be closely monitored. Symptoms of hypoglycaemia and bradycardia are generally to be expected within the first 3 days.

Use in lactation
Animal studies have shown that nebivolol is excreted in breast milk. It is not known whether this drug is excreted in human milk. Most beta-blockers, particularly lipophilic compounds like nebivolol and its active metabolites, pass into breast milk although to a variable extent. Therefore, breastfeeding is not recommended during administration of nebivolol.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. Pharmacodynamic studies have shown that 1/5 mg does not affect psychomotor function. When driving vehicles or operating machines it should be taken into account that dizziness and fatigue may occasionally occur.

4.8 Undesirable effects

Adverse events are listed separately for hypertension and CHF because of differences in the background diseases.

Hypertension
The adverse reactions reported, which are in most of the cases of mild to moderate intensity, are tabulated below, classified by system organ class and ordered by frequency:

<table>
<thead>
<tr>
<th>SYSTEM ORGAN CLASS</th>
<th>Common (≥1/100 to &lt; 1/10)</th>
<th>Uncommon (≥1/1,000 to ≤1/100)</th>
<th>Very Rare (≤1/10,000)</th>
<th>Not Known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td></td>
<td>angioneurotic oedema,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hypersensitivity</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td>nightmares; depression</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5 / 7
<table>
<thead>
<tr>
<th>Nervous system disorders</th>
<th>headache, dizziness, paraesthesia</th>
<th>syncope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye disorders</td>
<td>impaired vision</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>bradycardia, heart failure, slowed AV conduction/AV-block</td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>hypotension, (increase of) intermittent claudication</td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>dyspnoea</td>
<td>bronchospasm</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>constipation, nausea, diarrhoea</td>
<td>dyspepsia, flatulence, vomiting</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>pruritus, rash erythematous</td>
<td>psoriasis aggravated</td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td>impotence</td>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>tiredness, oedema</td>
<td></td>
</tr>
</tbody>
</table>

The following adverse reactions have also been reported with some beta-adrenergic antagonists: hallucinations, psychoses, confusion, cold/cyanotic extremities, Raynaud phenomenon, dry eyes, and oculo-mucocutaneous toxicity of the practolol-type.

**Chronic heart failure**

Data on adverse reactions in CHF patients are available from one placebo-controlled clinical trial involving 1067 patients taking nebivolol and 1061 patients taking placebo. In this study, a total of 449 nebivolol patients (42.1%) reported at least possibly causally related adverse reactions compared to 334 placebo patients (31.5%). The most commonly reported adverse reactions in nebivolol patients were bradycardia and dizziness, both occurring in approximately 11% of patients. The corresponding frequencies among placebo patients were approximately 2% and 7%, respectively.

The following incidences were reported for adverse reactions (at least possibly drug-related) which are considered specifically relevant in the treatment of chronic heart failure:

- Aggravation of cardiac failure occurred in 5.8% of nebivolol patients compared to 5.2% of placebo patients.
- Postural hypotension was reported in 2.1% of nebivolol patients compared to 1.0% of placebo patients.
- Drug intolerance occurred in 1.6% of nebivolol patients compared to 0.8% of placebo patients.
- First degree atrio-ventricular block occurred in 1.4% of nebivolol patients compared to 0.9% of placebo patients.
- Oedema of the lower limb were reported by 1.0% of nebivolol patients compared to 0.2% of placebo patients.

4.9 Overdose

No data are available on overdosage with /…/.

Symptoms
Symptoms of overdosage with beta-blockers are: bradycardia, hypotension, bronchospasm and acute cardiac insufficiency.

Treatment
In case of overdosage or hypersensitivity, the patient should be kept under close supervision and be treated in an intensive care ward. Blood glucose levels should be checked. Absorption of any drug residues still present in the gastro-intestinal tract can be prevented by gastric lavage and the administration of activated charcoal and a laxative. Artificial respiration may be required. Bradycardia or extensive vagal reactions should be treated by administering atropine or methylatropine. Hypotension and shock should be treated with plasma/plasma substitutes and, if necessary, catecholamines. The beta-blocking effect can be counteracted by slow intravenous administration of isoprenaline hydrochloride, starting with a dose of approximately 5 µg/minute, or dobutamine, starting with a dose of 2.5 µg/minute, until the required effect has been obtained. In refractory cases isoprenaline can be combined with dopamine. If this does not produce the desired effect either, intravenous administration of glucagon 50-100 µg/kg i.v. may be considered. If required, the injection should be repeated within one hour, to be followed -if required- by an i.v. infusion of glucagon 70 µg/kg/h. In extreme cases of treatment-resistant bradycardia, a pacemaker may be inserted.